CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects

被引：22

作者：

Estrela, R. C. E. ^{[1
]}

Santoro, A. B. ^{[1
]}

Barroso, P. F. ^{[2
]}

Tuyama, M. ^{[2
]}

Suarez-Kurtz, G. ^{[1
]}

机构：

[1] Inst Nacl Canc, Div Farmacol, Rio De Janeiro, Brazil

[2] Univ Fed Rio de Janeiro, Sch Med, Dept Prevent Med, Infect Dis Serv,Hosp Univ Clementino Fraga Filho, BR-21941 Rio De Janeiro, Brazil

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2008年 / 84卷 / 02期

关键词：

D O I：

10.1038/clpt.2008.12

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

CYP3A5 genotype has no impact on the trough plasma concentrations of lopinavir and ritonavir in human immunodeficiency virus (HIV)-infected individuals on stable highly active antiretroviral therapy (HAART). This is ascribed to a drug interaction, such that ritonavir by inhibiting CYP3A activity, may occlude the pharmacokinetic consequences of functional polymorphisms in the CYP3A5 gene. In the clinical setting, where lopinavir and ritonavir are always combined, CYP3A5 genotype is of no consequence on the trough plasma concentrations of these drugs.

引用

页码：205 / 207

页数：3

共 12 条

[1]

CROMMENTUYN KM, 2007, BR J CLIN PHARM, V60, P378

[2] Mechanism-based inactivation of CYP3A by HIV protease inhibitors [J].

Ernest, CS ;

Hall, SD ;

Jones, DR .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (02) :583-591

[3] Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro [J].

Granfors, MT ;

Wang, JS ;

Kajosaari, LI ;

Laitila, J ;

Neuvonen, PJ ;

Backman, JT .

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (01) :79-85

[4] CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir [J].

Josephson, F. ;

Allqvist, A. ;

Janabi, M. ;

Sayi, J. ;

Aklillu, E. ;

Jande, M. ;

Mahindi, M. ;

Burhenne, J. ;

Bottiger, Y. ;

Gustafsson, L. L. ;

Haefeli, W. E. ;

Bertilsson, L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) :708-712

[5]

Liu TC, 2002, ONCOL REP, V9, P327

[6] CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population [J].

Mirghani, Rajaa A. ;

Sayi, Jane ;

Aklillu, Eleni ;

Allqvist, Annika ;

Jande, Mary ;

Wennerholm, Agneta ;

Eriksen, Jaran ;

Herben, Virginie M. M. ;

Jones, Barry C. ;

Gustafsson, Lars L. ;

Bertilsson, Leif .

PHARMACOGENETICS AND GENOMICS, 2006, 16 (09) :637-645

[7] ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease [J].

Sham, HL ;

Kempf, DJ ;

Molla, A ;

Marsh, KC ;

Kumar, GN ;

Chen, CM ;

Kati, W ;

Stewart, K ;

Lal, R ;

Hsu, A ;

Betebenner, D ;

Korneyeva, M ;

Vasavanonda, S ;

McDonald, E ;

Saldivar, A ;

Wideburg, N ;

Chen, XQ ;

Niu, P ;

Park, C ;

Jayanti, V ;

Grabowski, B ;

Granneman, GR ;

Sun, E ;

Japour, AJ ;

Leonard, JM ;

Plattner, JJ ;

Norbeck, DW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) :3218-3224

[8] Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients [J].

Solas, C ;

Lafeuillade, A ;

Halfon, P ;

Chadapaud, S ;

Hittinger, G ;

Lacarelle, B .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :238-243

[9]

Suarez-Kurtz G, 2007, PHARMACOGENOMICS ADM, P75

[10] Impact of population admixture on the distribution of the CYP3A5*3 polymorphism [J].

Suarez-Kurtz, Guilherme ;

Perini, Jamila A. ;

Bastos-Rodrigues, Luciana ;

Pena, Sergio D. J. ;

Struchiner, Claudio .

PHARMACOGENOMICS, 2007, 8 (10) :1299-1306

← 1 2 →